Silvio Mandara, MD
Gynecology · Stamford, CTNPI 1134292881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,211 and has fallen 72.8% since, to $330 in 2025. Among gynecology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$618
- Astellas Pharma US Inc$448
- Novo Nordisk$254
- Takeda Pharmaceuticals U.S.A., Inc.$200
- Sumitomo Pharma America, Inc.$192
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,41399%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $1,042 |
| Amgen | 34 | $618 |
| Astellas Pharma US Inc | 19 | $448 |
| Novo Nordisk | 13 | $254 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $200 |
| Sumitomo Pharma America, Inc. | 9 | $192 |
| Urovant Sciences Inc | 7 | $191 |
| Avion Pharmaceuticals | 22 | $189 |
| Pfizer | 9 | $180 |
| Merck | 6 | $112 |
| Exact Sciences | 4 | $112 |
| Boehringer Ingelheim | 5 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $89 |
| CSL Behring | 4 | $76 |
| Lupin Inc. | 2 | $74 |
| Mayne Pharma Commercial LLC | 3 | $63 |
| Novartis | 2 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $41 |
| GSK | 2 | $40 |
| Eisai Inc. | 2 | $38 |
| Vertical Pharmaceuticals, LLC | 2 | $37 |
| Medtronic | 2 | $37 |
| Duchesnay USA Incorporated | 2 | $36 |
| Therapeuticsmd, Inc. | 2 | $36 |
| AstraZeneca | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Millicent US Inc | 1 | $18 |
How this compares
$4,436 in reported general payments places this provider in the 90th percentile of 39 gynecology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 22 | $37,826 |
| GemtesaVibegron | 19 | $24,330 |
| MyrbetriqMirabegron | 20 | $13,704 |
| Estradiol | 25 | $907 |
| Clobetasol Propionate | 32 | $854 |
| Bupropion XlBupropion Hcl | 13 | $515 |
| Alprazolam | 84 | $457 |
| Zolpidem Tartrate | 62 | $412 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $407 |
| Junel FeNorethindrone-E.Estradiol-Iron | 11 | $259 |
| Ibandronate Sodium | 11 | $168 |
| Fluconazole | 20 | $106 |
| Ciprofloxacin Hcl | 17 | $101 |
| Nystatin | 15 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia | $618 | $37,82622 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $192 | $24,33019 claims |
| Astellas Pharma US IncMyrbetriq | $448 | $13,70420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 gynecology providers in Connecticut.
Other gynecology in Stamford
- Scott ChudnoffStamford$30K
- Karli GoldsteinGreenwich$8K
- Roslyn ChosakNew Haven$3K
- Thomas McNameeNew Haven$3K
- Clare ManziMiddletown$2K
- Felice CollitonHartford$2K
- Elena Poloukhine MackenziePlainfield$2K
- Julie MalkinBristol$2K
- Danielle LucianoSouthington$2K
- Ann StrongGuilford$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.